

**Topics of Bachelor Theses  
 Spring Semester 2024**

<p>1.</p>	<p><b>ABOUT YOU GmbH IPO – DCF Analysis</b></p>	<p>ABOUT YOU GmbH, a Germany-based online clothing retailer, announced plans for an initial public offering during the summer of 2021. On June 16<sup>th</sup>, 2022, it was announced that the final offer price had been set at EUR 23 per share. Overall, the 31,832,300 shares covering the base offer valued the listing at EUR 841,964,335. Mr. Tarek Muller, co-founder and member of the management board, said that the IPO "[...] makes an exciting step toward realizing our vision of becoming the leading global fashion platform. We have gone from strength to strength since founding ABOUT YOU seven years ago, having established one of the largest European fashion offerings for Generation Y&amp;Z. But this is just the beginning. Fashion e-commerce will become even more digital, mobile, personalized, and inspirational in the years to come, and we are in a strong position to lead this transformation. "</p> <p>ABOUT YOU, founded in 2014, is a German fashion online retailer based in Hamburg. It is one of the fastest-growing e-commerce companies in Europe. The company's ambition is to digitalize the classic shopping stroll by creating an inspiring and personalized shopping experience on the smartphone.</p> <p>The goal of the thesis is to value ABOUT YOU using a DCF analysis and to determine whether the offer price of EUR 23 was fair. To do so, the student should conduct a comprehensive analysis of the industry and discuss the business model of ABOUT YOU.</p>	
-----------	---	--	--

<p>2.</p>	<p>ABOUT YOU GmbH IPO – Multiples and Event Study</p>	<p>ABOUT YOU GmbH, a Germany-based online clothing retailer, announced plans for an initial public offering during the summer of 2021. On June 16<sup>th</sup>, 2022, it was announced that the final offer price had been set at EUR 23 per share. Overall, the 31,832,300 shares covering the base offer valued the listing at EUR 841,964,335. Mr. Tarek Muller, co-founder and member of the management board, said that the IPO "[...] makes an exciting step toward realizing our vision of becoming the leading global fashion platform. We have gone from strength to strength since founding ABOUT YOU seven years ago, having established one of the largest European fashion offerings for Generation Y&amp;Z. But this is just the beginning. Fashion e-commerce will become even more digital, mobile, personalized, and inspirational in the years to come, and we are in a strong position to lead this transformation. "</p> <p>ABOUT YOU, founded in 2014, is a German fashion online retailer based in Hamburg. It is one of the fastest-growing e-commerce companies in Europe. The company's ambition is to digitalize the classic shopping stroll by creating an inspiring and personalized shopping experience on the smartphone.</p> <p>The goal of the thesis is to value ABOUT YOU with multiples of comparable companies and to analyze whether the offer price of EUR 23 was fair. An analysis of the stock price reaction to the IPO announcement for ABOUT YOU's competitors should complement the analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
-----------	---	--	--

<p>3.</p>	<p>Johnson &amp; Johnson acquires Abiomed – DCF Analysis</p>	<p>On November 1<sup>st</sup>, 2022, Johnson &amp; Johnson (NASDAQ: JNJ) announced that it had reached a definitive agreement with Abiomed Inc. (NASDAQ: ABMD), a Danvers, Massachusetts-based circulatory support and oxygenation medical manufacturer, to acquire 100% of the latter’s equity for USD 380 per share in cash. The offer price represents a bid premium of 50.75% based on Abiomed’s closing price prior to the announcement (USD 252.08 on October 31<sup>st</sup>, 2022). In addition, Abiomed’s shareholders will receive a contingent value right (CVR) to receive up to USD 35 per share if certain commercial and clinical milestones are achieved. Mr. Joaquin Duato, Johnson &amp; Johnson’s CEO, commented on the deal: “The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular diseases and helps more patients around the world while driving value for our shareholders.”</p> <p>Johnson &amp; Johnson, founded in 1886 as a manufacturer of surgical dressings, has grown into a multinational conglomerate selling a wide range of healthcare products under iconic brands worldwide. In 1981, Abiomed started to develop a fully implantable artificial heart called AbioCor. With a series of acquisitions thereafter, Abiomed further integrated cutting-edge technologies including Impella – the world’s smallest heart pump – and ECMO (extracorporeal membrane oxygenation) into its product portfolio. In 2019, it ranked 19<sup>th</sup> on <i>Fortune</i>’s list of 100 fastest-growing companies.</p> <p>The goal of the thesis is to value Abiomed using a DCF analysis and to estimate potential synergies from the transaction. The thesis should further investigate whether the transaction creates value for the shareholders of Abiomed and whether the offer price was fair.</p>	
-----------	--	---	--

<p>4.</p>	<p>Johnson &amp; Johnson acquires Abiomed – Multiples and Event Study</p>	<p>On November 1<sup>st</sup>, 2022, Johnson &amp; Johnson (NASDAQ: JNJ) announced that it had reached a definitive agreement with Abiomed Inc. (NASDAQ: ABMD), a Danvers, Massachusetts-based circulatory support and oxygenation medical manufacturer, to acquire 100% of the latter’s equity for USD 380 per share in cash. The offer price represents a bid premium of 50.75% based on Abiomed’s closing price prior to the announcement (USD 252.08 on October 31<sup>st</sup>, 2022). In addition, Abiomed’s shareholders will receive a contingent value right (CVR) to receive up to USD 35 per share if certain commercial and clinical milestones are achieved. Mr. Joaquin Duato, Johnson &amp; Johnson’s CEO, commented on the deal: “The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular diseases and helps more patients around the world while driving value for our shareholders.”</p> <p>Johnson &amp; Johnson, founded in 1886 as a manufacturer of surgical dressings, has grown into a multinational conglomerate selling a wide range of healthcare products under iconic brands worldwide. In 1981, Abiomed started to develop a fully implantable artificial heart called AbioCor. With a series of acquisitions thereafter, Abiomed further integrated cutting-edge technologies including Impella – the world’s smallest heart pump – and ECMO (extracorporeal membrane oxygenation) into its product portfolio. In 2019, it ranked 19<sup>th</sup> on <i>Fortune</i>’s list of 100 fastest-growing companies.</p> <p>The goal of the thesis is to value Abiomed using multiples at the time of a takeover announcement and to examine whether the offer price was fair. The thesis should further examine the price reactions of Johnson &amp; Johnson, Abiomed, and their competitors to the announcement using an event study analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
-----------	---	---	--

<p>5.</p>	<p>The Carve-out of Porsche – DCF Analysis</p>	<p>On September 19<sup>th</sup>, 2022, Volkswagen AG announced its plan to take its subsidiary Dr. Ing. h. c. F. Porsche public through an IPO. Rumors about the deal had started as far back as February 18<sup>th</sup>, 2022. Volkswagen intended to list up to 25% of Porsche on the Frankfurt Stock Exchange. Initial reports suggested that, even though Porsche’s CEO Mr. Oliver Blume supported the listing if Volkswagen pursued it, Volkswagen’s CEO Mr. Hebert Diess was not interested in the listing. On February 24<sup>th</sup>, 2022, Porsche and Volkswagen reached an agreement concerning the listing, and subject to shareholder approval, Porsche would proceed with the IPO.</p> <p>Volkswagen is an international leader in the automobile manufacturing industry headquartered in Germany. It was founded in 1937 and has steadily increased its market share through various acquisitions. Up until the carve-out, Porsche was a strong subsidiary of Volkswagen. Porsche specializes in producing high-performance sports cars, such as the iconic 911 model. In 2009, Volkswagen acquired a majority stake in Porsche AG.</p> <p>Porsche published the prospectus for the IPO on September 19<sup>th</sup>, 2022, and was divided into 911 million shares, half of which were ordinary shares and the other half preferred shares. Porsche issued 25% of the total preferred shares in the base offering with about 14.9 million shares as an over-allotment option. It set the issuing price between EUR 76.5 and EUR 82.5 per share. Eventually, the listing took place on September 29<sup>th</sup>, 2022, with an issue price of EUR 82.5, and a total of 113.875 million shares were issued.</p> <p>The goal of the thesis is to value Porsche using a DCF analysis and to determine whether the offer price of EUR 82.5 was fair. To do so, the student should conduct a comprehensive analysis of the industry and discuss the business model of Porsche.</p>	
-----------	--	---	--

<p>6.</p>	<p>The Carve-out of Porsche – Multiples and Event Study</p>	<p>On September 19<sup>th</sup>, 2022, Volkswagen AG announced its plan to take its subsidiary Dr. Ing. h. c. F. Porsche public through an IPO. Rumors about the deal had started as far back as February 18<sup>th</sup>, 2022. Volkswagen intended to list up to 25% of Porsche on the Frankfurt Stock Exchange. Initial reports suggested that, even though Porsche CEO Mr. Oliver Blume supported the listing if Volkswagen pursued it, Volkswagen CEO Mr. Hebert Diess was not interested in the listing. On February 24<sup>th</sup>, 2022, Porsche and Volkswagen reached an agreement concerning the listing, and subject to shareholder approval, Porsche would proceed with the IPO.</p> <p>Volkswagen is an international leader in the automobile manufacturing industry headquartered in Germany. It was founded in 1937 and has steadily increased its market share through various acquisitions. Up until the carve-out, Porsche was a strong subsidiary of Volkswagen. Porsche specializes in producing high-performance sports cars, such as the iconic 911 model. In 2009, Volkswagen acquired a majority stake in Porsche AG.</p> <p>Porsche published the prospectus for the IPO on September 19<sup>th</sup>, 2022, and was divided into 911 million shares, half of which were ordinary shares and the other half preferred shares. Porsche issued 25% of the total preferred shares in the base offering with about 14.9 million shares as an over-allotment option. It set the issuing price between EUR 76.5 and EUR 82.5 per share. Eventually, the listing took place on September 29<sup>th</sup>, 2022, with an issue price of EUR 82.5, and a total of 113.875 million shares were issued.</p> <p>The goal of the thesis is to value Porsche using multiples of comparable companies and to analyze whether the offer price of EUR 82.5 was fair. The thesis should further examine the price reactions of Volkswagen, Porsche, and their competitors to the announcement using an event study analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
-----------	---	---	--

7.	Mister Spex AG IPO – DCF Analysis	<p>On January 1<sup>st</sup>, 2021, Mister Spex AG, the Berlin-based online glasses and contact lenses retailer, reported it was looking to launch a listing on the Frankfurt Stock Exchange in the first half of the year. The listing could have a value between EUR 300 million and EUR 400 million and value the company at more than EUR 1 billion. On June 30<sup>th</sup>, 2021, Mister Spex set the issue price at EUR 25 per share. Overall, it issued 9,782,609 new shares via a capital increase and 3,260,869 existing shares from holdings of certain shareholders. It further allocated 1,956,521 existing shares as an overallotment option. Altogether, 14,999,999 shares are valued at EUR 374,999,975. Mister Spex successfully listed on July 2<sup>nd</sup>, 2021, under the ticker MRX.</p> <p>Mister Spex focuses on online and offline retail channels for eyewear in Europe. It operates a platform for fashionable and corrective eyewear, including prescription glasses, sunglasses, contact lenses, and contact lens care products. Mister Spex manages ten country-specific online stores across Europe and self-operated physical retail stores at major shopping locations in certain countries.</p> <p>The goal of the thesis is to value Mister Spex AG using a DCF analysis and to determine whether the offer price of EUR 25 was fair. To do so, the student should conduct a comprehensive analysis of the industry and discuss the business model of Mister Spex.</p>	
----	--------------------------------------	---	--

8.	Mister Spex AG IPO – Multiples and Event studies	<p>On January 1<sup>st</sup>, 2021, Mister Spex AG, the Berlin-based online glasses and contact lenses retailer, reported it was looking to launch a listing on the Frankfurt Stock Exchange in the first half of the year. The listing could have a value between EUR 300 million and EUR 400 million and value the company at more than EUR 1 billion. On June 30<sup>th</sup>, 2021, Mister Spex set the issue price at EUR 25 per share. Overall, it issued 9,782,609 new shares via a capital increase and 3,260,869 existing shares from holdings of certain shareholders. It further allocated 1,956,521 existing shares as an overallotment option. Altogether, 14,999,999 shares are valued at EUR 374,999,975. Mister Spex successfully listed on July 2<sup>nd</sup>, 2021, under the ticker MRX.</p> <p>Mister Spex focuses on online and offline retail channels for eyewear in Europe. It operates a platform for fashionable and corrective eyewear, including prescription glasses, sunglasses, contact lenses, and contact lens care products. Mister Spex manages ten country-specific online stores across Europe and self-operated physical retail stores at major shopping locations in certain countries.</p> <p>The goal of the thesis is to value Mister Spex with multiples of comparable companies and to analyze whether the offer price of EUR 25 was fair. An analysis of the stock price reaction to the IPO announcement for Mister Spex's competitors should complement the analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
----	--	--	--



<p>9.</p>	<p>ONEOK acquires Magellan Midstream Partners – DCF Analysis</p>	<p>On May 14<sup>th</sup>, 2023, ONEOK Inc. (NYSE: OKE) announced that it had reached an agreement with Magellan Midstream Partners, L.P. (NYSE: MMP) to acquire the latter, paying USD 25 in cash plus 0.6670 ONEOK common shares for each outstanding common unit held by Magellan’s shareholders. The offer represents a total value of USD 18.8 billion (including assumed debt) and a bid premium of 23.02% (based on Magellan’s closing price on May 11<sup>th</sup>, 2023). The transaction “brings together two premier energy infrastructure businesses with strong returns on invested capital and diverse free cash flow generation: The transaction adds a leading, and primarily fee-based, refined products and crude oil transportation business to ONEOK,” ONEOK said in a news release.</p> <p>Magellan primarily transports, stores, and distributes refined petroleum products and crude oil. Incorporated in 2000, the company owns a refined petroleum products pipeline system in the US and can store more than 100 million barrels of petroleum products, such as gasoline, diesel fuel, and crude oil. ONEOK is a midstream service provider owning natural gas liquids (NGLs) systems that connect producers and end-users and a network of natural gas gathering, processing, storage, and transportation assets. Originally founded in 1906 as an interstate natural gas pipeline business in Oklahoma, the company has become an industry leader.</p> <p>The goal of the thesis is to value Magellan Midstream Partners using a DCF analysis and to estimate potential synergies from the transaction. The thesis should further investigate whether the transaction creates value for the shareholders of Magellan Midstream Partners and whether the offer price was fair.</p>	
-----------	--	---	--

<p>10.</p>	<p>ONEOK acquires Magellan Midstream Partners – Multiples and Event studies</p>	<p>On May 14<sup>th</sup>, 2023, ONEOK Inc. (NYSE: OKE) announced that it had reached an agreement with Magellan Midstream Partners, L.P. (NYSE: MMP) to acquire the latter, paying USD 25 in cash plus 0.6670 ONEOK common shares for each outstanding common unit held by Magellan’s shareholders. The offer represents a total value of USD 18.8 billion (including assumed debt) and a bid premium of 23.02% (based on Magellan’s closing price on May 11<sup>th</sup>, 2023). The transaction “brings together two premier energy infrastructure businesses with strong returns on invested capital and diverse free cash flow generation: The transaction adds a leading, and primarily fee-based, refined products and crude oil transportation business to ONEOK,” ONEOK said in a news release.</p> <p>Magellan primarily transports, stores, and distributes refined petroleum products and crude oil. Incorporated in 2000, the company owns a refined petroleum products pipeline system in the US and can store more than 100 million barrels of petroleum products, such as gasoline, diesel fuel, and crude oil. ONEOK is a midstream service provider owning natural gas liquids (NGLs) systems that connect producers and end-users and a network of natural gas gathering, processing, storage, and transportation assets. Originally founded in 1906 as an interstate natural gas pipeline business in Oklahoma, the company has become an industry leader.</p> <p>The goal of the thesis is to value Midstream Partners using multiples at the time of a takeover announcement and to examine whether the offer price was fair. The thesis should further examine the price reactions of ONEOK, Midstream Partners, and their competitors on the announcement date using an event study analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
------------	---	--	--

<p>11.</p>	<p>Cherry AG IPO – DCF Analysis</p>	<p>On June 7<sup>th</sup>, 2021, Cherry AG, a Munich-based computer input device manufacturer, announced its intention to list on the Frankfurt Stock Exchange. The listing would consist of primary shares for proceeds of approximately EUR 140 million and an undisclosed volume of secondary shares. The overall base offer included 9.3 million shares with an additional 3.695 million shares as a potential over-allotment option. On June 23<sup>rd</sup>, 2021, Cherry set the price per share at EUR 32, valuing the base offer at EUR 297.6 million. On June 29<sup>th</sup>, 2021, the transaction was completed. The transaction was oversubscribed, including the over-allotment option, valuing the company at EUR 415.83 million. Mr. Rolf Unterberger, CEO of Cherry, said “Cherry is the worldwide leading manufacturer of switches for the premium gaming mechanical keyboard market. We are at an exciting growth stage and are looking forward to this next chapter in Cherry’s development.”</p> <p>Cherry is a globally active manufacturer of high-end switches for mechanical keyboards and computer input devices. Its business focuses on mechanical keyboard switches for gaming keyboards and computer input devices used in various settings, mainly for gaming, office, industry, cybersecurity protection, and telematics solutions for healthcare practices. Since its foundation in 1953, Cherry has stood with its two business areas: Gaming (comprising the Gaming Switches and the Gaming Peripherals business units) and Professional (comprising the Office &amp; Industry Peripherals and the Healthcare &amp; Security Peripherals business units).</p> <p>The goal of the thesis is to value Cherry AG using a DCF analysis and to determine whether the offer price of EUR 32 was fair. To do so, the student should conduct a comprehensive analysis of the industry and discuss the business model of Cherry AG.</p>	
------------	-------------------------------------	--	--

<p>12.</p>	<p>Cherry AG IPO –                  Multiples and                  Event Studies</p>	<p>On June 7<sup>th</sup>, 2021, Cherry AG, a Munich-based computer input device manufacturer, announced its intention to list on the Frankfurt Stock Exchange. The listing would consist of primary shares for proceeds of approximately EUR 140 million and an undisclosed volume of secondary shares. The overall base offer included 9.3 million shares with an additional 3.695 million shares as a potential over-allotment option. On June 23<sup>rd</sup>, 2021, Cherry set the price per share at EUR 32, valuing the base offer at EUR 297.6 million. On June 29<sup>th</sup>, 2021, the transaction was completed. The transaction was oversubscribed, including the over-allotment option, valuing the company at EUR 415.83 million. Mr. Rolf Unterberger, CEO of Cherry, said “Cherry is the worldwide leading manufacturer of switches for the premium gaming mechanical keyboard market. We are at an exciting growth stage and are looking forward to this next chapter in Cherry’s development.”</p> <p>Cherry is a globally active manufacturer of high-end switches for mechanical keyboards and computer input devices. Its business focuses on mechanical keyboard switches for gaming keyboards and computer input devices used in various settings, mainly for gaming, office, industry, cybersecurity protection, and telematics solutions for healthcare practices. Since its foundation in 1953, Cherry has stood with its two business areas: Gaming (comprising the Gaming Switches and the Gaming Peripherals business units) and Professional (comprising the Office &amp; Industry Peripherals and the Healthcare &amp; Security Peripherals business units).</p> <p>The goal of the thesis is to value Cherry AG with multiples of comparable companies and to analyze whether the offer price of EUR 32 was fair. An analysis of the stock price reaction to the IPO announcement for Cherry AG’s competitors should complement the analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
------------	--	--	--

<p>13.</p>	<p>Pfizer Inc. acquires Global Blood Therapeutics – DCF Analysis</p>	<p>On August 8<sup>th</sup>, 2022, Pfizer Inc. (NYSE: PFE) announced that it had entered into a definitive agreement to acquire Global Blood (NYSE: GBT). Pfizer would pay USD 68.5 per share of Global Blood, in cash. The estimated enterprise value is USD 5.4 billion. Based on the closing share price of USD 63.84 on August 8<sup>th</sup>, 2022, the last trading day before the announcement, this offer represents an announced bid premium of 7.3%. Based on the closing share price of USD 32.93 on August 2<sup>nd</sup>, 2022, the last trading day before the rumour, this offer represents a rumour bid premium of 108%. Mr. Ted W. Love, CEO of Global Blood, said "Pfizer will broaden and amplify our impact for patients and further propel much-needed innovation and resources for the care of people with sickle cell disease and other rare diseases, including populations in limited-resource countries. We look forward to working together with Pfizer to serve our communities and advance our shared goal of improving health equity and expanding access to life-changing treatments to create a healthier future for all."</p> <p>Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Diseases, and Inflammation &amp; Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients.</p> <p>The goal of the thesis is to value Global Blood Therapeutics using a DCF analysis and to estimate potential synergies from the transaction. The thesis should further investigate whether the transaction creates value for the shareholders of Global Blood Therapeutics and whether the offer price was fair.</p>	
------------	--	---	--

<p>14.</p>	<p>Pfizer Inc. acquires Global Blood Therapeutics – Multiples and Event studies</p>	<p>On August 8<sup>th</sup>, 2022, Pfizer Inc. (NYSE: PFE) announced that it had entered into a definitive agreement to acquire Global Blood (NYSE: GBT). Pfizer would pay USD 68.5 per share of Global Blood, in cash. The estimated enterprise value is USD 5.4 billion. Based on the closing share price of USD 63.84 on August 8<sup>th</sup>, 2022, the last trading day before the announcement, this offer represents an announced bid premium of 7.3%. Based on the closing share price of USD 32.93 on August 2<sup>nd</sup>, 2022, the last trading day before the rumour, this offer represents a rumour bid premium of 108%. Mr. Ted W. Love, CEO of Global Blood, said "Pfizer will broaden and amplify our impact for patients and further propel much-needed innovation and resources for the care of people with sickle cell disease and other rare diseases, including populations in limited-resource countries. We look forward to working together with Pfizer to serve our communities and advance our shared goal of improving health equity and expanding access to life-changing treatments to create a healthier future for all."</p> <p>Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Diseases, and Inflammation &amp; Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients.</p> <p>The goal of the thesis is to value Global Blood Therapeutics using multiples at the time of a takeover announcement and to examine whether the offer price was fair. The thesis should further examine the price reactions of Pfizer Inc., Global Blood Therapeutics, and their competitors to the announcement using an event study analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
------------	---	---	--

<p>15.</p>	<p>L3Harris acquires Aerojet Rocketdyne – DCF Analysis</p>	<p>On December 19<sup>th</sup>, 2022, L3Harris Technologies, Inc. (NYSE: LHX) announced that it had reached an agreement with Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD), a California-based aerospace and defence manufacturer, to acquire the latter in an all-cash deal valued at USD 3.6 billion. The offer price was USD 58 per share, representing a bid premium of 5.67% based on Aerojet Rocketdyne’s closing price prior to the announcement (USD 54.89 per share on December 16<sup>th</sup>, 2022). On October 25<sup>th</sup> of the same year, Aerojet Rocketdyne was reportedly soliciting acquisition offers. Among the interested companies were General Electric Company, Textron, Veritas Capital Partners, as well as L3Harris. By the time of the announcement, the target’s stock price had risen by more than 20%. The deal might face strong opposition from the industry and strict scrutiny from the regulators. Constant consolidation in the US defence industry has led to growing antitrust concerns. On February 15<sup>th</sup>, 2022, the Federal Trade Commission blocked an attempted acquisition of Aerojet Rocketdyne by Lockheed Martin following opposition from Raytheon, arguing that the deal would give the acquirer unfair market power over its competitors.</p> <p>L3Harris is an international communication and information technology company offering a wide range of products, systems and services to defence, civil, government and commercial customers. In 2021, deriving over 80% of its revenue from the defence sector, L3Harris ranked 7th by revenue among the largest US defence contractors. Aerojet Rocketdyne is a US manufacturer of liquid and solid rocket propulsion, air-breathing engines, and electric power and propulsion for space, defence, civil and commercial applications. Its customers include prime contractors to the US government, DoD, and NASA.</p> <p>The goal of the thesis is to value Aerojet Rocketdyne using a DCF analysis and to estimate potential synergies from the transaction. The thesis should further investigate whether the transaction creates value for the shareholders of Aerojet Rocketdyne and whether the offer price was fair.</p>	
------------	--	--	--

<p>16.</p>	<p>L3Harris acquires Aerojet Rocketdyne – Multiples and Event studies</p>	<p>On December 19<sup>th</sup>, 2022, L3Harris Technologies, Inc. (NYSE: LHX) announced that it had reached an agreement with Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD), a California-based aerospace and defence manufacturer, to acquire the latter in an all-cash deal valued at USD 3.6 billion. The offer price was USD 58 per share, representing a bid premium of 5.67% based on Aerojet Rocketdyne’s closing price prior to the announcement (USD 54.89 per share on December 16<sup>th</sup>, 2022). On October 25<sup>th</sup> of the same year, Aerojet Rocketdyne was reportedly soliciting acquisition offers. Among the interested companies were General Electric Company, Textron, Veritas Capital Partners, as well as L3Harris. By the time of the announcement, the target’s stock price had risen by more than 20%. The deal might face strong opposition from the industry and strict scrutiny from the regulators. Constant consolidation in the US defence industry has led to growing antitrust concerns. On February 15<sup>th</sup>, 2022, the Federal Trade Commission blocked an attempted acquisition of Aerojet Rocketdyne by Lockheed Martin following opposition from Raytheon, arguing that the deal would give the acquirer unfair market power over its competitors.</p> <p>L3Harris is an international communication and information technology company offering a wide range of products, systems and services to defence, civil, government and commercial customers. In 2021, deriving over 80% of its revenue from the defence sector, L3Harris ranked 7th by revenue among the largest US defence contractors. Aerojet Rocketdyne is a US manufacturer of liquid and solid rocket propulsion, air-breathing engines, and electric power and propulsion for space, defence, civil and commercial applications. Its customers include prime contractors to the US government, DoD, and NASA.</p> <p>The goal of the thesis is to value Aerojet Rocketdyne using multiples at the time of a takeover announcement and to examine whether the offer price was fair. The thesis should further examine the price reactions of L3Harris, Aerojet Rocketdyne, and their competitors on the announcement date using an event study analysis. In addition, the author should examine other key dates during the negotiation process.</p>	
------------	---	--	--